Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

(Securities Code 4694)
June 5, 2020

To Shareholders with Voting Rights:

Kensuke Kondo
President and Representative Director
BML, Inc.
5-21-3 Sendagaya, Shibuya-ku, Tokyo

NOTICE OF THE 65TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

We would like to express our appreciation for your continued support and patronage.

You are hereby informed that the 65th Annual General Meeting of Shareholders of BML, Inc. (the "Company") will be held for the purposes as described below.

In order to prevent the spread of novel coronavirus disease (COVID-19), the Japanese government and prefectural governors are strongly recommending all persons to stay at home. In response to this situation, as a result of careful consideration, we will be holding the General Meeting of Shareholders upon conducting appropriate infection preventive measures.

Under the situation of strong recommendation to stay at home, we would like to ask all our shareholders to exercise your voting rights in advance in writing or via the Internet, etc. as much as possible instead of attending the General Meeting of Shareholders from the perspective of preventing the spread of COVID-19, regardless of your physical condition.

Please review the attached Reference Documents for the General Meeting of Shareholders, and exercise your voting rights no later than 5:30 p.m. on Thursday, June 25, 2020, Japan time.

1. **Date and Time:** Friday, June 26, 2020 at 10:00 a.m. Japan time
2. **Place:** Nishiki, South Tower 4F, Keio Plaza Hotel
   2-2-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
   In order to prevent the spread of COVID-19, we will make a space between seats at this General Meeting of Shareholders. Accordingly, the number of seats available to the shareholders will be substantially fewer than previous years. Therefore, you may be denied admission.. Thank you very much for your understanding in advance.
3. **Meeting Agenda:**

Matters to be reported:

1. The Business Report, Consolidated Financial Statements for the Company's 65th Fiscal Year (April 1, 2019 - March 31, 2020) and results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Board of Corporate Auditors
2. Non-consolidated Financial Statements for the Company's 65th Fiscal Year (April 1, 2019 - March 31, 2020)

Proposals to be resolved:

Proposal 1: Distribution of Surplus
Proposal 2: Election of 11 Directors
Proposal 3: Election of 1 Substitute Corporate Auditor

○ When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk.
○ You may exercise your voting rights by mail or electronic media (via the Internet, etc.). By following "Guidance for Exercise of Voting Rights" on pages 3 and 4, please exercise your voting rights no later than 5:30 p.m. on Thursday, June 25, 2020 Japan time.
○ In the event that voting rights are exercised multiple times via the Internet, etc., only the final vote submitted shall be considered valid.
○ In the event that voting rights are exercised both by mailing the Voting Rights Exercise Form and via the Internet, etc., the voting rights exercised through the Internet, etc. shall be considered valid.
○ Any updates to the Reference Documents for the General Meeting of Shareholders, the Business Report, the Non-Consolidated Financial Statements, and the Consolidated Financial Statements will be posted on the Company's website (http://www.bml.co.jp).

<Notes to shareholders>

- We may update the above measures depending upon the situation of the spread of the disease and announcements made by the government until the day of the General Meeting of Shareholders. Please check the Company's website (http://www.bml.co.jp) on the Internet for the transmission of information.
- Exercising your voting rights by the Voting Rights Exercise Form entails infection risk during the course of sending back the Form and counting the votes. Therefore, if you are exercising your voting rights in advance, we would like to ask you to do so via the Internet as much as possible.
- We will place alcohol disinfectants for you to use near the reception desk at the venue.
  (If you are attending the meeting, we would like to request you to bring and wear a face mask.)
- We will take your temperature near the venue. Shareholders that have a fever, seem to be in a poor physical condition, or came back to Japan from overseas within 14 days may be asked not to enter the venue and go home. Please notify the receptionist if you came back to Japan and 14 days have not yet passed.
- Operation staff of the General Meeting of Shareholders will take their temperatures, confirm their physical condition, and wear a face mask.
- From the viewpoint of shortening the meeting in order to prevent the spread of COVID-19, detailed explanation on matters to be reported (including audit reports) and on the proposals will be omitted. We would like to ask you to read through the Notice in advance.

Reference Documents for the General Meeting of Shareholders

Proposals and References

Proposal 1: Distribution of Surplus

The Company recognizes the appropriate return of profits to shareholders as one of its important management priorities and intends to strive for improvement of the dividend level commensurate with the consolidated financial results based on the basic policy of maintaining continuous, stable dividends.

The year-end dividend of surplus for this year shall be paid as follows, based on such basic policy.

Items Related to the Year-end Dividend

(1) Type of dividend property

Cash

(2) Items related to the allocation of dividend property and the total amount

25.0 yen per common share of the Company

Total amount: 1,015,542,775 yen

The annual dividend for this year will be 45.0 yen per share including the interim dividend of 20.0 yen per share which has been already paid.

(3) Date the distribution of surplus comes into effect

June 29, 2020

Proposal 2: Election of 11 Directors

The terms of office of all 12 Directors will expire at the conclusion of this General Meeting of Shareholders. Accordingly, the election of 11 Directors is proposed.

The candidates for Directors are as follows. Matters on the candidates for Directors are provided in pages 6 to 15.

No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
1	Kensuke Kondo (Reappointment)	President and Representative Director	100.0% 15 out of 15 times
2	Nobuki Arai (Reappointment)	Representative Director; Senior Executive Officer; General Manager, Management Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office	100.0% 15 out of 15 times
3	Masato Chikira (Reappointment)	Director; Executive Officer; General Manager, System Division; General Manager, Electronic Patient Chart System Department	93.3% 14 out of 15 times
4	Masao Nakagawa (Reappointment)	Director; Executive Officer; General Manager, Inspection Management Division; General Manager, Satellite Inspection Division	100.0% 15 out of 15 times
5	Satoshi Enomoto (Reappointment)	Director; Operating Officer; in charge of Special Missions; in charge of Risk Management Department	100.0% 15 out of 15 times
6	Norihisa Takebe (Reappointment)	Director; Operating Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department	100.0% 15 out of 15 times

No.	Name	Positions and responsibilities in the Company	Attendance at meetings of the Board of Directors
7	Yasushi Narabe (Reappointment)	Director; Operating Officer; General Manager, General Laboratory Inspection Division; General Manager, Inspection Department I; General Manager, Inspection Department II; General Manager, Inspection Department IV; General Manager, Reagent Department; General Manager, Operations Management Department	100.0% 15 out of 15 times
8	Hideaki Osawa (Reappointment)	Director; Operating Officer; General Manager, Sales Management Division; General Manager, Proposal Planning Department	100.0% 11 out of 11 times
9	Kouichi Sekiya (Reappointment) (Outside) (Independent)	Director	100.0% 15 out of 15 times
10	Toshiyuki Kondo (Reappointment) (Outside) (Independent)	Director	100.0% 11 out of 11 times
11	Yukiko Yoritaka (New appointment) (Outside) (Independent)		

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
1	Kensuke Kondo (September 18, 1966) (Reappointment)	May 1994 Obtained a medical license June 1994 Director of the Company June 2004 Operating Officer in charge of medical science June 2006 Director; Operating Officer in charge of medical science October 2011 Director; Operating Officer; General Manager, Advanced Technology & Development Division; Deputy General Manager, Sales Management Division April 2013 Director; Operating Officer; Deputy General Manager, Management Division January 2014 President and Representative Director To present [Significant concurrent positions] ・Chairman and Representative Director, Daiichi Kishimoto Clinical Laboratories, Inc. ・Chairman and Representative Director, Okayama Medical Laboratory Company ・Chairman and Representative Director, Kyodo Igaku Laboratories, Inc. ・Chairman and Representative Director, PCL Japan, Inc. ・Chairman and Representative Director, Japan Clinical Service, Inc. ・Chairman and Representative Director, OPL, Inc. ・President and Representative Director, BML Planning, Inc. ・President and Representative Director, Estate Kogyo Limited Company (Reasons for nomination) Dr. Kensuke Kondo has abundant experience and deep insight on overall medical industry from his experience as a doctor. Since assuming position as Representative Director in January 2014, he has been leading the Group's management. Based on his wealth of achievement from his excellent leadership, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	3,571,316

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
2	Nobuki Arai (March 30, 1960) (Reappointment)	May 1989 Obtained a medical license May 1989 Worked for University of Toyama Hospital June 2005 Outside Corporate Auditor of the Company April 2007 Medical Director, Keiyu Hospital June 2009 Director of the Company December 2009 Director; Executive Officer; Director, BML General Laboratory July 2012 Director; Executive Officer; General Manager, General Laboratory Inspection Division; Director, BML General Laboratory April 2013 Director; Executive Officer; General Manager, General Laboratory Inspection Division; General Manager, Advanced Technology & Development Division; Director, BML General Laboratory January 2014 Director; Executive Officer; General Manager, Inspection Management Division; Director, BML General Laboratory June 2015 Director; Senior Executive Officer in charge of Sales Management Division; Director, BML General Laboratory February 2017 Director; Senior Executive Officer; General Manager, Planning Division; Director, BML General Laboratory June 2017 Representative Director; Senior Executive Officer; General Manager, Planning Division; in charge of Credit Guarantee Department; Director, BML General Laboratory June 2018 Representative Director; Senior Executive Officer; General Manager, Planning Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office April 2020 Representative Director; Senior Executive Officer; General Manager, Management Division; in charge of Credit Guarantee Department; Director, BML General Laboratory; General Manager, Overseas Business Office To present (Reasons for nomination) Dr. Nobuki Arai has abundant experience and deep insight on overall medical industry from his experience as a doctor. Since assuming position as a Director in June 2009, he has served positions in inspection, sales, planning and quality divisions, and after assuming position as Representative Director in June 2017, he has involved in the Company's overall business including overseas and management divisions. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	66,793

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
3	Masato Chikira (May 25, 1955) (Reappointment)	July 1979 Joined the Company February 1996 General Manager, System Department, System Division August 1998 Deputy General Manager, System Division June 2008 Operating Officer; Deputy General Manager, System Division June 2012 Director; Operating Officer; Deputy General Manager, System Division June 2014 Director; Executive Officer; General Manager, System Division; General Manager, Electronic Patient Chart System Department To present (Reasons for nomination) Since joining the Company, Mr. Masato Chikira has involved mainly in the systems division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him as a candidate for Director.	5,457

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
4	Masao Nakagawa (January 30, 1955) (Reappointment)	April 1979 Joined the Company November 2005 General Manager, Satellite Management Department July 2007 Director; Inspection Manager, Tokyo Koshueisei Laboratories, Inc. June 2009 General Manager, Satellite Management Department, the Company July 2012 Operating Officer; Deputy General Manager, Satellite Inspection Division February 2013 Operating Officer; General Manager, Satellite Inspection Division June 2014 Director; Operating Officer; General Manager, Satellite Inspection Division June 2015 Director; Executive Officer; General Manager, Inspection Management Division; General Manager, Satellite Inspection Division To present (Reasons for nomination) Since joining the Company, Mr. Masao Nakagawa has involved mainly in the inspection division and has abundant experience and deep insight on the Company's overall business as a medical technologist. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	2,609

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
5	Satoshi Enomoto (May 28, 1961) (Reappointment)	April 1984 Joined the Japan Travel Bureau (currently JTB Corp.) April 2008 Joined the Company Deputy General Manager, Management Division June 2009 General Manager, General Affairs Department June 2013 General Manager, Sales Management Department January 2014 General Manager, Sales Management Department; General Manager, Accounting Department June 2014 Operating Officer; General Manager, Sales Management Department; General Manager, Accounting Department April 2015 Operating Officer; Deputy General Manager, Management Division June 2015 Operating Officer; Deputy General Manager, Management Division; General Manager, Personnel Department June 2016 Director; Operating Officer; General Manager, Management Division; General Manager, Personnel Department June 2018 Director; Operating Officer; General Manager, Management Division; General Manager, Personnel Department; in charge of Risk Management Department June 2019 Director; Operating Officer; General Manager, Management Division; in charge of Risk Management Department April 2020 Director; Operating Officer; in charge of Special Missions; in charge of Risk Management Department To present (Reasons for nomination) Since joining the Company, Mr. Satoshi Enomoto has involved mainly in general affairs, accounting and personnel divisions and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	2,230

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
6	Norihisa Takebe (April 28, 1962) (Reappointment)	April 1987 Joined The Kyowa Bank, Ltd. (currently Resona Bank, Limited) April 2013 General Manager, Yokohama Branch April 2015 Joined the Company General Manager, Sales Management Department; General Manager, Accounting Department June 2015 General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department October 2015 General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department April 2016 Operating Officer; General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department June 2016 Director; Operating Officer; Deputy General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Related Business Department; General Manager, Sales Management Department; General Manager, Accounting Department April 2019 Director; Operating Officer; Deputy General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department April 2020 Director; Operating Officer; General Manager, Planning Division; General Manager, Corporate Planning Department; General Manager, Sales Management Department; General Manager, Accounting Department To present (Reasons for nomination) Mr. Norihisa Takebe has knowledge and experience of financial business. Since joining the Company, he has involved mainly in accounting, corporate planning and group company management divisions and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	2,305

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
7	Yasushi Narabe (July 20, 1959) (Reappointment)	April 1982 Joined the Company April 2012 General Manager, Automatic Analysis Department April 2014 General Manager, General Laboratory Inspection Division; General Manager, Inspection Department II; General Manager, Microbial Inspection Department; General Manager, Operations Management Department June 2015 Operating Officer; General Manager, General Laboratory Inspection Division; General Manager, Inspection Planning Department; General Manager, Inspection Department I; General Manager, Inspection Department II; General Manager, Inspection Department IV; General Manager, Microbial Inspection Department; General Manager, Reagent Department; General Manager, Operations Management Department June 2018 Director; Operating Officer; General Manager, General Laboratory Inspection Division; General Manager, Inspection Department I; General Manager, Inspection Department II; General Manager, Inspection Department IV; General Manager, Reagent Department; General Manager, Operations Management Department To present (Reasons for nomination) Since joining the Company, Mr. Yasushi Narabe has involved mainly in inspection division and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	4,330

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
8	Hideaki Osawa (February 13, 1964) (Reappointment)	September 1986 Joined the Company June 2001 General Manager, Sales Office I, Clinical Inspection Sales Department July 2008 General Manager, Kinki Sales Department June 2010 Representative Director, Japan Clinical Service, Inc. June 2015 Deputy General Manager, Sales Management Division April 2016 Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Tokyo Branch July 2018 Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Kanto Branch June 2019 Director; Operating Officer; Deputy General Manager, Sales Management Division; General Manager, Proposal Planning Department April 2020 Director; Operating Officer; General Manager, Sales Management Division; General Manager, Proposal Planning Department To present (Reasons for nomination) Since joining the Company, Mr. Hideaki Osawa has involved mainly in sales division as well as serving as Representative Director at a collection-related subsidiary, and has abundant experience and deep insight on the Company's overall business. By utilizing such achievements, expertise as well as insights on management, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Director.	2,221
9	Kouichi Sekiya (June 6, 1945) (Reappointment) (Outside) (Independent)	April 1970 Joined Showa Denko K.K. November 2000 Councillor; General Manager, Production Technology Department, Production Technology Headquarters, Head Office March 2004 Corporate Officer; General Manager, Gases and Chemicals Division, Chemicals Sector June 2005 Corporate Officer; General Manager, Chemicals Production Center, Chemicals Sector January 2006 President and Representative Director, SHOWA ENGINEERING CO., LTD. June 2018 Outside Director of the Company To present (Reasons for nomination) Based on abundant experience, deep insight and expertise on years of corporate management at chemical industry, Mr. Kouichi Sekiya has made opinions and judgements from objective standpoint when making decisions for the management of the Company, and also played a role of monitoring and supervising Directors' execution of duties. From these above, the Company has judged that he is personnel necessary to increase future corporate value of the Group, and therefore nominates him again as a candidate for Outside Director. It has been two years since the appointment of Mr. Kouichi Sekiya as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.	648

No.	Name (Date of birth)	Past experience, positions and responsibilities in the Company	Number of shares of the Company held
10	Toshiyuki Kondo (October 24, 1946) (Reappointment) (Outside) (Independent)	July 1976 Obtained a medical license April 1980 Medical Economics Division, Health Insurance Bureau; Health Statistics Division, Statistics and Information Department September 1990 Joined SRL, Inc. July 1995 President and Representative Director April 2006 Director General, Chiba Prefectural Hospitals Bureau April 2011 Managing Director, Miyagi Prefectural Hospital Organization January 2013 Senior Managing Director, VHJ Organization (NPO) June 2019 Outside Director of the Company To present [Significant concurrent positions] ・Managing Director, Miyagi Prefectural Hospital Organization (Reasons for nomination) Dr. Toshiyuki Kondo has abundant experience and deep insights on overall medical industry from his experience as a doctor, as well as abundant experience and deep insights on corporate management. By utilizing such achievements, expertise as well as insights on management, the Company judged that he is a personnel necessary to increase future corporate value of the Group to make opinions and judgements from objective standpoint when making decisions for the management of the Company, and to play a role of monitoring and supervising Directors' execution of duties, and therefore nominates him again as a candidate for Outside Director. It has been one year since the appointment of Dr. Toshiyuki Kondo as Outside Director of the Company as of the conclusion of this Annual General Meeting of Shareholders.	0
11	Yukiko Yoritaka (July 9, 1964) (New appointment) (Outside) (Independent)	April 1987 Joined The Sumitomo Bank, Limited (currently Sumitomo Mitsui Banking Corporation) April 2016 Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Banking Corporation; Representative Director and President, SMBC LEARNING SUPPORT CO., LTD. April 2017 Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Banking Corporation; Representative Director and President, SMBC LEARNING SUPPORT CO., LTD.; Executive Officer; General Manager, Learning and Development Institute, Human Resources Department, Sumitomo Mitsui Financial Group, Inc. April 2020 Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Banking Corporation; Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Financial Group, Inc. To present [Significant concurrent positions] ・Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Banking Corporation ・Executive Officer; Deputy in charge of Human Resources Department, Sumitomo Mitsui Financial Group, Inc. (Reasons for nomination) Ms. Yukiko Yoritaka has abundant experience and deep insights on finance and human resources fields currently as Executive Officer of Sumitomo Mitsui Banking Corporation. By utilizing such achievements, expertise as well as insights on management, the Company judged that she is a personnel necessary to increase future corporate value of the Group to make opinions and judgements from objective standpoint when making decisions for the management of the Company, and to play a role of monitoring and supervising Directors' execution of duties, and therefore nominates her as a candidate for Outside Director.	0

(Notes)

1. There are no special interests between the candidates for Directors and the Company.
2. Attendance at meetings of the Board of Directors for Mr. Hideaki Osawa and Dr. Toshiyuki Kondo aggregate the meetings held after they assumed their position.
3. Mr. Kouichi Sekiya, Dr. Toshiyuki Kondo and Ms. Yukiko Yoritaka are candidates for Outside Directors.
4. The Company has appointed Mr. Kouichi Sekiya and Dr. Toshiyuki Kondo as Independent Directors prescribed by the Tokyo Stock Exchange.
5. If Ms. Yukiko Yoritaka is elected as proposed, the Company will appoint her as an Independent Director prescribed by the Tokyo Stock Exchange.
6. The Company has entered into an agreement with Mr. Kouichi Sekiya and Dr. Toshiyuki Kondo in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liabilities pursuant to Article 423, Paragraph 1 of the same act. The maximum amount of liability pursuant to the agreement is the minimum amount stipulated by laws and regulations. If they are reelected and takes office as Outside Directors of the Company, the agreement shall continue to be effective.
7. If Ms. Yukiko Yoritaka is elected as proposed, the Company intends to enter into an agreement with her in accordance with Article 427, Paragraph 1 of the Companies Act to limit her liability pursuant to Article 423, Paragraph 1 of the same act. The maximum amount of liability pursuant to the agreement will be the minimum amount stipulated by laws and regulations.
8. The number of shares of the Company held by each candidate for Director refers to the actual number of shares held by each of them including the shares under the BML Group officers' shareholding association.

Proposal 3: Election of 1 Substitute Corporate Auditor

In order to prepare for cases where a vacancy results in a shortfall in the number of Corporate Auditors prescribed by laws and regulations, we propose the election of one Substitute Corporate Auditor.

The Board of Corporate Auditors has previously given its approval to this proposal.

The candidate for Substitute Corporate Auditor is as follows:

Name (Date of birth)	Past experience and significant concurrent positions	Number of shares of the Company held
Shunsuke Nohara (November 11, 1979) (Outside)	October 2006 Registered as attorney at law (Dai-ichi Tokyo Bar Association) Joined KOHWA SOHGOH LAW OFFICES August 2015 Joined Kelvin Chia Partnership January 2016 Admitted as attorney at law in New York, USA October 2016 Partner, KOHWA SOHGOH LAW OFFICES (incumbent) To present (Reasons for nomination) The Company proposes that Mr. Shunsuke Nohara be elected as Substitute Corporate Auditor since we judged that his expertise as an attorney at law and abundant experience as a corporate lawyer can be used for enhancing the audit structure of the Company, even though he has never been involved in corporate management.	0

(Notes)

1. Mr. Shunsuke Nohara is a candidate for Substitute Outside Corporate Auditor.
2. The Company has not entered into an advisory contract with the candidate.
3. The Company has entered into agreements with Outside Corporate Auditors in accordance with Article 427, Paragraph 1 of the Companies Act to limit their liability pursuant to Article 423, Paragraph 1 of the same act. The maximum amount of liability pursuant to the agreements is the minimum amount stipulated by laws and regulations. If the candidate is elected and takes office as Outside Corporate Auditor, the Company intends to conclude the same agreement with him.
4. Mr. Shunsuke Nohara satisfies the requirement as Independent Corporate Auditor prescribed by the Tokyo Stock Exchange. If he assumes office as Outside Corporate Auditor, the Company will appoint him as an Independent Corporate Auditor prescribed by the Tokyo Stock Exchange.